BIIB$196.58
Biogen Inc.
Moat Score
37/100
Biogen retains a narrow moat built around specialized neurology franchises, entrenched physician relationships, and regulatory barriers in rare disease markets. Its strongest products benefit from clinical familiarity and some switching friction, but the company lacks the network effects, scale economics, and broad pricing power that define a wide moat. The franchise is also vulnerable to patent expiration, biosimilar pressure, and pipeline volatility, while the Aduhelm episode and the loss of several legacy growth drivers weakened investor confidence in the durability of its edge. The low score reflects the moat’s limited breadth rather than a total absence of defensible assets. Overall, the competitive position remains real but is trending negative as the portfolio matures and newer launches must prove lasting commercial strength.
Sign in to see the full analysis
The Strategic Factor Breakdown, Management Quality Assessment, and AI Impact Assessment are available to registered users — it's free.
Financial Score
64/100
BIIB’s most notable strength is its improving liquidity and disciplined cash generation, which provide a solid buffer despite uneven operating performance. Current assets have expanded well above current liabilities, the current and quick ratios have strengthened materially, and free cash flow remains healthy, supported by modest capital spending and conservative financing. That said, the income statement is more mixed: revenue declined for several years before stabilizing, gross margins remain strong, but operating and net earnings have not returned to prior peaks and have been distorted by non-core items. Leverage is manageable and equity has grown, yet the balance sheet still carries meaningful debt and a large goodwill/intangible base. Growth looks modest rather than robust, with low-single-digit revenue recovery and an expected EPS rebound later in the forecast. Overall, BIIB presents a stable but only moderately compelling financial profile, consistent with its midrange ratings.
Sign in to see the full analysis
The Income Statement, Balance Sheet, Cash Flow, Key Ratios, Forecast, and Fair Value analysis are available to registered users — it's free.
Sign In to Run AI-Powered Technical Analysis
Create a free account to run a fresh technical analysis across three timeframes — short, medium, and long term.
Disclaimer: The analysis on this page is generated by AI and is provided for informational purposes only. It does not constitute financial advice, investment recommendations, or an offer to buy or sell any security. Always conduct your own due diligence and consult a qualified financial adviser before making any investment decisions.